摘要
根治性手术切除是目前胆囊癌可获得治愈和长期生存的最有效方法。但进展期胆囊癌患者由于发现较晚，其手术切除率较低，疗效欠佳。新辅助化疗可使部分肿瘤降期并获得手术切除机会，提高根治性手术切除率，在食管癌、胃癌和结直肠癌等肿瘤患者的疗效已经得到肯定。胆囊癌新辅助化疗目前尚未广泛开展。本文通过回顾胆囊癌化疗的现状、进展及相关化疗方案的有效性，探讨了在进展期胆囊癌患者开展新辅助化疗的可行性及目前存在的一些主要问题。
Radical resection has been the only therapeutic method that can improve the long-term survival for patients with gallbladder cancer （GBC） so far. However, for advanced GBC, patients generally have poor prognosis due to late awareness of the disease and poor surgical resection rate. Sometimes, the neoadjuvant chemotherapy can downstage tumors for potential surgery thus increases the R0 resection rate, as confirmed in esophageal carcinoma, gastric carcinoma, colorectal carcinoma, and so on. Currently, the neoadjuvant chemotherapy in GBC has not been extensively performed. In this article, we will review the recent progression, current status, and effectiveness of associated regimens of chemotherapy treatment of GBC,as well as discussing the feasibility of delivering neoadjuvant chemotherapy to the patients with advanced GBC and solutions to major issues.
出处
《中华肝胆外科杂志》
CSCD
北大核心
2017年第11期789-792,共4页
Chinese Journal of Hepatobiliary Surgery
基金
国家自然科学基金（81572420）
关键词
胆囊癌
化疗
新辅助化疗
Gallbladder cancer
Chemotherapy
Neoadjuvant chemotherapy
